MarketScreener Editorial Features Gubra A/S
Equities
GUBRA
DK0062266474
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 336.60 DKK | -10.24% |
|
-16.94% | -37.86% |
| 08:26am | Gubra's partner AbbVie reports positive phase 1 results for ABBV-295 | RE |
| Mar. 06 | Gubra A/S, 2025 Pre Recorded Earnings Call, Feb 27, 2026 |
MarketScreener Editorial Features
Search
 | AbbVie: stepping up obesity treatments with an alternative approach to GLP-1 | January 15, 2026 at 03:06 am EST |
No results for this search
- Stock Market
- Equities
- GUBRA Stock
- News Gubra A/S
- MarketScreener Editorial Features
Select your edition
All financial news and data tailored to specific country editions
